MAP kinase phosphatase 1 (MKP-1/DUSP1) isneuroprotective in Huntington's disease via additive effects of JNK and p38 inhibition

Journal of Neuroscience

Volumn 33, Issue 6, 2013, Pages 2313-2325

  Taylor, David M ^a   Moser, Roger ^a   Régulier, Etienne ^a   Breuillaud, Lionel ^b   Dixon, Meredith ^a   Beesen, Ayshe Ana ^c   Elliston, Linda ^d   Santos, Mariana de Fatima Silva ^e   Kim, Jinho ^f   Jones, Lesley ^d   Goldstein, Darlene R ^a   Ferrante, Robert J ^f,g   Luthi Carter, Ruth ^a,c,e  

^a EPFL   (Switzerland)

^b Hopital de Cery   (Switzerland)

^c Alzheimer's Research Unit   (United States)

^d CARDIFF UNIVERSITY   (United Kingdom)

^e UNIVERSITY OF LEICESTER   (United Kingdom)

^f UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^g VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 NITROPROPIONIC ACID; CASPASE 3; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; MITOGEN ACTIVATED PROTEIN KINASE PHOSPHATASE 1; NEURON SPECIFIC NUCLEAR PROTEIN; STRESS ACTIVATED PROTEIN KINASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL VIABILITY; CONTROLLED STUDY; EMBRYO; FEMALE; GENE OVEREXPRESSION; GENE SILENCING; HUNTINGTON CHOREA; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; MICROARRAY ANALYSIS; MOUSE; NERVE CELL NECROSIS; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ANIMALS; CELLS, CULTURED; DUAL SPECIFICITY PHOSPHATASE 1; FEMALE; HUNTINGTON DISEASE; MAP KINASE KINASE 4; MICE; NEUROPROTECTIVE AGENTS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; RATS; RATS, WISTAR;

EID: 84873298611     PISSN: 02706474     EISSN: 15292401     Source Type: Journal    
DOI: 10.1523/JNEUROSCI.4965-11.2013     Document Type: Article

References (68)

1. Apostol BL, Illes K, Pallos J, Bodai L, Wu J, Strand A, Schweitzer ES, Olson JM, Kazantsev A, Marsh JL, Thompson LM (2006) Mutant huntingtin alters MAPK signaling pathways in PC12 and striatal cells: ERK1/2 protects against mutant huntingtin-associated toxicity. Hum Mol Genet 15:273-285. CrossRef Medline
2. Apostol BL, Simmons DA, Zuccato C, Illes K, Pallos J, Casale M, Conforti P, Ramos C, Roarke M, Kathuria S, Cattaneo E, Marsh JL, Thompson LM (2008) CEP-1347 reduces mutant huntingtin-associated neurotoxicity and restores BDNF levels in R6/2 mice. Mol Cell Neurosci 39:8-20. CrossRef Medline
3. Bai L, Yoon SO, King PD, Merchant JL (2004) ZBP-89-induced apoptosis is p53-independent and requires JNK. Cell Death Differ 11:663-673. CrossRef Medline
4. Bemelmans AP, Horellou P, Pradier L, Brunet I, Colin P, Mallet J (1999) Brain-derived neurotrophic factor-mediated protection of striatal neurons in an excitotoxic rat model of Huntington's disease, as demonstrated by adenoviral gene transfer. Hum Gene Ther 10:2987-2997. CrossRef Medline
5. Borsello T, Forloni G (2007) JNK signalling: a possible target to prevent neurodegeneration. Curr Pharm Des 13:1875-1886. CrossRef Medline
6. Bowen EJ, Schmidt TW, Firm CS, Russo AF, Durham PL (2006) Tumor necrosis factor-alpha stimulation of calcitonin gene-related peptide expression and secretion from rat trigeminal ganglion neurons. J Neurochem 96:65-77. CrossRef Medline
7. Brondello JM, Pouysségur J, McKenzie FR (1999) Reduced MAP kinase phosphatase-1 degradation after p42/p44MAPK-dependent phosphorylation. Science 286:2514-2517. CrossRef Medline
8. Charvin D, Vanhoutte P, Pagès C, Borrelli E, Borelli E, Caboche J (2005) Unraveling a role for dopamine in Huntington's disease: the dual role of reactive oxygen species and D2 receptor stimulation. Proc Natl Acad Sci U S A 102:12218-12223. CrossRef Medline
9. Choi BH, Hur EM, Lee JH, Jun DJ, Kim KT (2006) Protein kinase Cδ- mediated proteasomal degradation of MAP kinase phosphatase-1 contributes to glutamate-induced neuronal cell death. J Cell Sci 119: 1329-1340. CrossRef Medline
10. Cuny GD (2009) Kinase inhibitors as potential therapeutics for acute and chronic neurodegenerative conditions. Curr Pharm Des 15:3919-3939. CrossRef Medline
11. de Almeida LP, Ross CA, Zala D, Aebischer P, Déglon N (2002) Lentiviral-mediated delivery of mutant huntingtin in the striatum of rats induces a selective neuropathology modulated by polyglutamine repeat size, huntingtin expression levels, and protein length. J Neurosci 22:3473-3483. Medline
12. Dedeoglu A, Kubilus JK, Jeitner TM, Matson SA, Bogdanov M, Kowall NW, Matson WR, Cooper AJ, Ratan RR, Beal MF, Hersch SM, Ferrante RJ (2002) Therapeutic effects of cystamine in a murine model of Huntington's disease. J Neurosci 22:8942-8950. Medline
13. Duric V, Banasr M, Licznerski P, Schmidt HD, Stockmeier CA, Simen AA, Newton SS, Duman RS (2010) A negative regulator of MAP kinase causes depressive behavior. Nat Med 16:1328-1332. CrossRef Medline
14. Eljaschewitsch E, Witting A, Mawrin C, Lee T, Schmidt PM, Wolf S, Hoertnagl H, Raine CS, Schneider-Stock R, Nitsch R, Ullrich O (2006) The endocannabinoid anandamide protects neurons during CNS inflammation by induction of MKP-1 in microglial cells. Neuron 49:67-79. CrossRef Medline
15. Farooq A, Zhou MM (2004) Structure and regulation of MAPK phosphatases. Cell Signal 16:769-779. CrossRef Medline
16. Ferrante RJ, Kubilus JK, Lee J, Ryu H, Beesen A, Zucker B, Smith K, Kowall NW, Ratan RR, Luthi-Carter R, Hersch SM (2003) Histone deacetylase inhibition by sodium butyrate chemotherapy ameliorates the neurodegenerative phenotype in Huntington's disease mice. J Neurosci 23:9418-9427. Medline
17. Ferrante RJ, Ryu H, Kubilus JK, D'Mello S, Sugars KL, Lee J, Lu P, Smith K, Browne S, Beal MF, Kristal BS, Stavrovskaya IG, Hewett S, Rubinsztein DC, Langley B, Ratan RR (2004) Chemotherapy for the brain: the antitumor antibiotic mithramycin prolongs survival in a mouse model of Huntington's disease. J Neurosci 24:10335-10342. CrossRef Medline
18. Finegan KG, Wang X, Lee EJ, Robinson AC, Tournier C (2009) Regulation of neuronal survival by the extracellular signal-regulated protein kinase 5. Cell Death Differ 16:674-683. CrossRef Medline
19. Franklin CC, Kraft AS (1995) Constitutively active MAP kinase kinase (MEK1) stimulates SAP kinase and c-Jun transcriptional activity in U937 human leukemic cells. Oncogene 11:2365-2374. Medline
20. Gambazzi L, Gokce O, Seredenina T, Katsyuba E, Runne H, Markram H, Giugliano M, Luthi-Carter R (2010) Diminished activity-dependent brain-derived neurotrophic factor expression underlies cortical neuron microcircuit hypoconnectivity resulting from exposure to mutant huntingtin fragments. J Pharmacol Exp Ther 335:13-22. CrossRef Medline
21. Garcia M, Vanhoutte P, Pages C, Besson MJ, Brouillet E, Caboche J (2002) The mitochondrial toxin 3-nitropropionic acid induces striatal neurodegeneration via a c-Jun N-terminal kinase/c-Jun module. J Neurosci 22: 2174-2184. Medline
22. Gianfriddo M, Melani A, Turchi D, Giovannini MG, Pedata F (2004) Adenosine and glutamate extracellular concentrations and mitogen-activated protein kinases in the striatum of Huntington transgenic mice: selective antagonism of adenosine A2A receptors reduces transmitter outflow. Neurobiol Dis 17:77-88. CrossRef Medline
23. Gokce O, Runne H, Kuhn A, Luthi-Carter R (2009) Short-term striatal gene expression responses to brain-derived neurotrophic factor are dependent on MEK and ERK activation. PLoS One 4:e5292. CrossRef Medline
24. Gomez-Lazaro M, Galindo MF, Melero-Fernandez de Mera RM, Fernandez-Gómez FJ, Concannon CG, Segura MF, Comella JX, Prehn JH, Jordan J (2007) Reactive oxygen species and p38 mitogenactivated protein kinase activate Bax to induce mitochondrial cytochrome c release and apoptosis in response to malonate. Mol Pharmacol 71:736-743. CrossRef Medline
25. Groom LA, Sneddon AA, Alessi DR, Dowd S, Keyse SM (1996) Differential regulation of the MAP, SAP and RK/p38 kinases by Pyst1, a novel cytosolic dual-specificity phosphatase. EMBO J 15:3621-3632. Medline
26. Haagenson KK, Wu GS (2010) Mitogen activated protein kinase phosphatases and cancer. Cancer Biol Ther 9:337-340. CrossRef Medline
27. Hodges A, Strand AD, Aragaki AK, Kuhn A, Sengstag T, Hughes G, Elliston LA, Hartog C, Goldstein DR, Thu D, Hollingsworth ZR, Collin F, Synek B, Holmans PA, Young AB, Wexler NS, Delorenzi M, Kooperberg C, Augood SJ, Faull RL, Olson JM, Jones L, Luthi-Carter R. (2006) Regional and cellular gene expression changes in human Huntington's disease brain. Hum Mol Genet 15:965-977. CrossRef Medline
28. Horita H, Wada K, Rivas MV, Hara E, Jarvis ED (2010) The dusp1 immediate early gene is regulated by natural stimuli predominantly in sensory input neurons. J Comp Neurol 518:2873-2901. CrossRef Medline
29. Huntington's Disease Collaborative Research Group (1993) A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes: the Huntington's Disease Collaborative Research Group. Cell 72:971-983. CrossRef Medline
30. Jan HJ, Lee CC, Lin YM, Lai JH, Wei HW, Lee HM (2009) Rosiglitazone reduces cell invasiveness by inducing MKP-1 in human U87MG glioma cells. Cancer Lett 277:141-148. CrossRef Medline
31. Jeanneteau F, Deinhardt K, Miyoshi G, Bennett AM, Chao MV (2010) The MAP kinase phosphatase MKP-1 regulates BDNF-induced axon branching. Nat Neurosci 13:1373-1379. CrossRef Medline
32. Karunakaran S, Saeed U, Mishra M, Valli RK, Joshi SD, Meka DP, Seth P, Ravindranath V (2008) Selective activation of p38 mitogen-activated protein kinase in dopaminergic neurons of substantia nigra leads to nuclear translocation of p53 in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridinetreated mice. J Neurosci 28:12500-12509. CrossRef Medline
33. Kawahara N, Wang Y, Mukasa A, Furuya K, Shimizu T, Hamakubo T, Aburatani H, Kodama T, Kirino T (2004) Genome-wide gene expression analysis for induced ischemic tolerance and delayed neuronal death following transient global ischemia in rats. J Cereb Blood Flow Metab 24: 212-223. CrossRef Medline
34. Kells AP, Fong DM, Dragunow M, During MJ, Young D, Connor B (2004) AAV-mediated gene delivery of BDNF or GDNF is neuroprotective in a model of Huntington disease. Mol Ther 9:682-688. CrossRef Medline
35. Keshet Y, Seger R (2010) The MAP kinase signaling cascades: a system of hundreds of components regulates a diverse array of physiological functions. Methods Mol Biol 661:3-38. CrossRef Medline
36. Kuhn A, Goldstein DR, Hodges A, Strand AD, Sengstag T, Kooperberg C, Becanovic K, Pouladi MA, Sathasivam K, Cha JH, Hannan AJ, Hayden MR, Leavitt BR, Dunnett SB, Ferrante RJ, Albin R, Shelbourne P, Delorenzi M, Augood SJ, Faull RL, Olson JM, Bates GP, Jones L, Luthi-Carter R. (2007) Mutant Huntington's effects on striatal gene expression in mice recapitulate changes observed in human Huntington's disease brain and do not differ with mutant huntingtin length or wild-type huntingtin dosage. Hum Mol Genet 16:1845-1861. CrossRef Medline
37. Lee ST, Park JE, Kim DH, Kim S, Im WS, Kang L, Jung SH, Kim MW, Chu K, KimM (2008) Granulocyte-colony stimulating factor attenuates striatal degeneration with activating survival pathways in 3-nitropropionic acid model of Huntington's disease. Brain Res 1194:130-137. CrossRef Medline
38. Lin YM, Jan HJ, Lee CC, Tao HY, Shih YL, Wei HW, Lee HM (2008) Dexamethasone reduced invasiveness of human malignant glioblastoma cells through a MAPK phosphatase-1 (MKP-1) dependent mechanism. Eur J Pharmacol 593:1-9. CrossRef Medline
39. Liu L, Cavanaugh JE, Wang Y, Sakagami H, Mao Z, Xia Z (2003) ERK5 activation of MEF2-mediated gene expression plays a critical role in BDNF-promoted survival of developing but not mature cortical neurons. Proc Natl Acad Sci U S A 100:8532-8537. CrossRef Medline
40. Liu YF (1998) Expression of polyglutamine-expanded Huntingtin activates the SEK1-JNK pathway and induces apoptosis in a hippocampal neuronal cell line. J Biol Chem 273:28873-28877. CrossRef Medline
41. Luthi-Carter R (2007) Huntington's and other polyglutamine diseases: many effects of single gene mutations. Drug Discov Today 4:111-119. CrossRef
42. Luthi-Carter R, Hanson SA, Strand AD, Bergstrom DA, Chun W, Peters NL, Woods AM, Chan EY, Kooperberg C, Krainc D, Young AB, Tapscott SJ, Olson JM (2002) Dysregulation of gene expression in the R6/2 model of polyglutamine disease: parallel changes in muscle and brain. Hum Mol Genet 11:1911-1926. CrossRef Medline
43. Magi-Galluzzi C, Mishra R, Fiorentino M, Montironi R, Yao H, Capodieci P, Wishnow K, Kaplan I, Stork PJ, Loda M (1997) Mitogen-activated protein kinase phosphatase 1 is overexpressed in prostate cancers and is inversely related to apoptosis. Lab Invest 76:37-51. Medline
44. Marie-Claire C, Benturquia N, Lundqvist A, Courtin C, Noble F (2008) Characteristics of dual specificity phosphatases mRNA regulation by 3,4- methylenedioxymethamphetamine acute treatment in mice striatum. Brain Res 1239:42-48. CrossRef Medline
45. Merienne K, Helmlinger D, Perkin GR, Devys D, Trottier Y (2003) Polyglutamine expansion induces a protein-damaging stress connecting heat shock protein 70 to the JNK pathway. J Biol Chem 278:16957-16967. CrossRef Medline
46. Mishra OP, Delivoria-Papadopoulos M (2004) Effect of hypoxia on the expression and activity of mitogen-activated protein (MAP) kinasephosphatase- 1 (MKP-1) and MKP-3 in neuronal nuclei of newborn piglets: the role of nitric oxide. Neuroscience 129:665-673. CrossRef Medline
47. Muda M, Boschert U, Dickinson R, Martinou JC, Martinou I, Camps M, Schlegel W, Arkinstall S (1996) MKP-3, a novel cytosolic proteintyrosine phosphatase that exemplifies a new class of mitogen-activated protein kinase phosphatase. J Biol Chem 271:4319-4326. CrossRef Medline
48. Munoz L, Ammit AJ (2010) Targeting p38 MAPK pathway for the treatment of Alzheimer's disease. Neuropharmacology 58:561-568. CrossRef Medline
49. Obara Y, Nakahata N (2010) The signaling pathway leading to extracellular signal-regulated kinase 5 (ERK5) activation via G-proteins and ERK5- dependent neurotrophic effects. Mol Pharmacol 77:10-16. CrossRef Medline
50. Patterson KI, Brummer T, O'Brien PM, Daly RJ (2009) Dual-specificity phosphatases: critical regulators with diverse cellular targets. Biochem J 418:475-489. CrossRef Medline
51. Perrin V, Dufour N, Raoul C, Hassig R, Brouillet E, Aebischer P, Luthi-Carter R, Déglon N (2009) Implication of the JNK pathway in a rat model of Huntington's disease. Exp Neurol 215:191-200. CrossRef Medline
52. Rangone H, Poizat G, Troncoso J, Ross CA, MacDonald ME, Saudou F, Humbert S (2004) The serum- and glucocorticoid-induced kinase SGK inhibits mutant huntingtin-induced toxicity by phosphorylating serine 421 of huntingtin. Eur J Neurosci 19:273-279. CrossRef Medline
53. Reijonen S, Kukkonen JP, Hyrskyluoto A, Kivinen J, Kairisalo M, Takei N, Lindholm D, Korhonen L (2010) Downregulation of NF-k{cyrillic}B signaling by mutant huntingtin proteins induces oxidative stress and cell death. Cell Mol Life Sci 67:1929-1941. CrossRef Medline
54. Roze E, Betuing S, Deyts C, Marcon E, Brami-Cherrier K, Pagès C, Humbert S, Mérienne K, Caboche J (2008) Mitogen- and stress-activated protein kinase-1 deficiency is involved in expanded-huntingtininduced transcriptional dysregulation and striatal death. FASEB J 22: 1083-1093. Medline
55. Rudinskiy N, Kaneko YA, Beesen AA, Gokce O, Régulier E, Déglon N, Luthi-Carter R (2009) Diminished hippocalcin expression in Huntington's disease brain does not account for increased striatal neuron vulnerability as assessed in primary neurons. J Neurochem 111:460-472. CrossRef Medline
56. Scotter EL, Goodfellow CE, Graham ES, Dragunow M, Glass M (2010) Neuroprotective potential of CB1 receptor agonists in an in vitro model of Huntington's disease. Br J Pharmacol 160:747-761. CrossRef Medline
57. Slack DN, Seternes OM, Gabrielsen M, Keyse SM (2001) Distinct binding determinants for ERK2/p38alpha and JNKMAPkinases mediate catalytic activation and substrate selectivity of MAP kinase phosphatase-1. J Biol Chem 276:16491-16500. CrossRef Medline
58. Stack EC, Del Signore SJ, Luthi-Carter R, Soh BY, Goldstein DR, Matson S, Goodrich S, Markey AL, Cormier K, Hagerty SW, Smith K, Ryu H, Ferrante RJ (2007) Modulation of nucleosome dynamics in Huntington's disease. Hum Mol Genet 16:1164-1175. CrossRef Medline
59. Sun H, Charles CH, Lau LF, Tonks NK (1993) MKP-1 (3CH134), an immediate early gene product, is a dual specificity phosphatase that dephosphorylates MAP kinase in vivo. Cell 75:487-493. CrossRef Medline
60. Tanoue T, Yamamoto T, Nishida E (2002) Modular structure of a docking surface on MAPK phosphatases. J Biol Chem 277:22942-22949. CrossRef Medline
61. Thu DC, Oorschot DE, Tippett LJ, Nana AL, Hogg VM, Synek BJ, Luthi-Carter R, Waldvogel HJ, Faull RL (2010) Cell loss in the motor and cingulate cortex correlates with symptomatology in Huntington's disease. Brain 133:1094-1110. CrossRef Medline
62. Varma H, Cheng R, Voisine C, Hart AC, Stockwell BR (2007) Inhibitors of metabolism rescue cell death in Huntington's disease models. Proc Natl Acad Sci U S A 104:14525-14530. CrossRef Medline
63. Varma H, Yamamoto A, Sarantos MR, Hughes RE, Stockwell BR (2010) Mutant huntingtin alters cell fate in response to microtubule depolymerization via the GEF-H1-RhoA-ERK pathway. J Biol Chem 285: 37445-37457. CrossRef Medline
64. Wang L, Ankati H, Akubathini SK, Balderamos M, Storey CA, Patel AV, Price V, Kretzschmar D, Biehl ER, D'Mello SR (2010) Identification of novel 1,4-benzoxazine compounds that are protective in tissue culture and in vivo models of neurodegeneration. J Neurosci Res 88: 1970-1984. CrossRef Medline
65. Zala D, Benchoua A, Brouillet E, Perrin V, Gaillard MC, Zurn AD, Aebischer P, Déglon N (2005) Progressive and selective striatal degeneration in primary neuronal cultures using lentiviral vector coding for a mutant huntingtin fragment. Neurobiol Dis 20:785-798. CrossRef Medline
66. Zhou J, Wang L, Ling S, Zhang X (2007) Expression changes of growthassociated protein-43 (GAP-43) and mitogen-activated protein kinase phosphatase-1 (MKP-1) and in hippocampus of streptozotocin-induced diabetic cognitive impairment rats. Exp Neurol 206:201-208. CrossRef Medline
67. Zuccato C, Ciammola A, Rigamonti D, Leavitt BR, Goffredo D, Conti L, MacDonald ME, Friedlander RM, Silani V, Hayden MR, Timmusk T, Sipione S, Cattaneo E (2001) Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease. Science 293:493-498. CrossRef Medline
68. Zuccato C, Liber D, Ramos C, Tarditi A, Rigamonti D, Tartari M, Valenza M, Cattaneo E (2005) Progressive loss of BDNF in a mouse model of Huntington's disease and rescue by BDNF delivery. Pharmacol Res 52:133-139. CrossRef Medline